GlassScriptPhysician profile
Eileen Ingenito
NPI 1386731784
$4,485.57
in general payments reported to CMS, 2019-2025
28 companies · $794 in 2025
The $794 reported for 2025 was more than what 83% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.22 · 2022: $1,593 · 2023: $1,171 · 2024: $858 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,822.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $513.23 | 2022-2024 | Xolair |
| Neurocrine Biosciences, INC. | $433.11 | 2022-2025 | Ingrezza |
| Inspire Medical Systems, INC. | $369.52 | 2022-2023 | Inspire |
| Alexion Pharmaceuticals, INC. | $360.39 | 2023-2025 | Koselugo, Strensiq |
| Amgen INC. | $274.99 | 2024-2025 | Krystexxa, Repatha |
| Gilead Sciences, INC. | $250.00 | 2024 | Veklury, Epclusa |
| Teva Pharmaceuticals USA, INC. | $215.83 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $161.75 | 2022 | |
| Biogen, INC. | $142.15 | 2023 | Spinraza |
| Mylan Specialty L.P. | $125.00 | 2024 | Yupelri |
| Organogenesis INC. | $124.99 | 2023 | Puraply Antimicrobial |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.99 | 2023 | |
| Janssen Scientific Affairs, LLC | $124.94 | 2022 | |
| Abbvie INC. | $124.59 | 2022 | |
| Esperion Therapeutics, INC. | $124.58 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $124.47 | 2022 | |
| Novo Nordisk INC | $120.18 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $118.24 | 2025 | Airsupra |
| Alkermes, INC. | $117.02 | 2021-2022 | |
| Neurelis, INC. | $104.63 | 2023-2024 | Valtoco |
| Amarin Pharma, INC. | $88.10 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $87.37 | 2023 | Trudhesa |
| Advanced Oxygen Therapy INC. | $87.32 | 2023 | Topical Oxygen Chamber For Extremities |
| Corium, LLC | $59.20 | 2023-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $47.69 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $27.39 | 2025 | Cobenfy |
| Pfizer INC. | $18.90 | 2025 | |
| Merck Sharp & Dohme LLC | $15.00 | 2025 | Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Ingenito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.